With all the expression datasets that are available to the public, wouldn’t it be great to compare them to your own expression data, so you could get a better understanding of the underlying biology of your data? With QIAGEN IPA Analysis Match, you can compare your expression data with well over 100,000 publicly available datasets […]
In this training, you will learn how to analyze and interpret your own single-cell RNA-seq data using QIAGEN CLC Genomics Workbench starting with either FASTQ or matrix files. Using CLC Genomics Workbench, you will learn how to perform secondary analysis on your single-cell RNA-seq data. Specifically, you will learn how to: • Import your raw […]
Cancer cell line models have been a cornerstone of cancer research for decades. Profiling cancer cell lines can be a powerful tool to identify gene alterations or cancer-related pathways and aid in discovering putative drug targets. In this webinar, we'll use QIAGEN OmicSoft Lands and QIAGEN Ingenuity Pathway Analysis (IPA) to help you select cell […]
In an era of near-limitless public experimental data but little standardization, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny. In this webinar, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Knowledge Base […]
The cancer drug discovery landscape is shifting. While research continues to grow in cost and complexity, the pace of development has never been faster. Biopharmaceutical companies can’t afford to waste time and resources pursuing ineffective or unsafe ideas. In this talk, our experts discuss how biopharmaceutical companies can leverage key genomic, biomedical, and clinical trial […]
Single-cell RNA-sequencing (scRNA-seq) is widely used to investigate tissue heterogeneity, identify novel cell types, study pathogenic mechanisms, develop targeted therapy (including immunotherapy) and more. Accordingly, a tremendous amount of scRNA-seq data has been deposited to public domains like GEO. In this training, you will learn how to · Locate public single-cell studies of interest using QIAGEN Omicsoft […]
In this webinar, users will learn how to leverage solutions from QIAGEN Digital Insights to discover biomarkers, validate targets, and identify variants. Specifically, users will learn: 1. How to locate public studies of interest using OmicSoft DiseaseLand. 2. Investigate the expression of genes of interest across different treatments, disease states, etc. 3. Identify variants of […]
Join us for a 120-minute training session for new users of QIAGEN IPA. In this training, you’ll learn how to: Upload your dataset (RNA-seq, scRNA-seq, proteomics, metabolomics and more) and perform interactive core/pathway analysis in IPA Understand the different result types produced (pathways, key regulators, impact on biological functions/diseases and more) Compare different experimental conditions […]
Whether your lab is researching and developing targeted cancer therapies or you are analyzing and interpreting diagnostic tests at the point-of-care, a critical part of your workflow is understanding the structural and functional impact of cancer-related mutations. The Catalogue Of Somatic Mutations In Cancer (COSMIC) is an expert-curated database encompassing a wide variety of somatic mutation […]
Cancer cell line models have been a cornerstone of cancer research for decades. Profiling cancer cell lines can be a powerful tool to identify gene alterations or cancer-related pathways and aid in discovering putative drug targets. In this webinar, we'll use QIAGEN OmicSoft Lands and QIAGEN Ingenuity Pathway Analysis (IPA) to help you select cell […]
Over the past decade, whole-exome and whole-genome sequencing have transformed the diagnosis of patients with suspected rare genetic diseases. However, despite recent advancements, a large number of patients with rare genetic diseases remains undiagnosed for years because they have limited access to comprehensive genomic testing. In this virtual roundtable of leading rare disease experts, panelists […]
In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, […]
Industry leaders discuss how to improve the speed, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases Clinical exome testing is revolutionizing the diagnosis of rare and inherited diseases. Its ability to quickly pinpoint the genetic causes of complex conditions has made it a critical component of personalized medicine, […]
Watch NowIn this training, you will learn how to analyze viral samples using QIAGEN CLC Genomics Workbench. This webinar will focus on bioinformatics workflows and data interpretation using H5N1 as an example, but similar analysis can be done with other viral and microbial (bacteria, fungus and more) samples. Using viral samples, you will learn how to: […]
Watch NowMore and more biopharma and academic groups are looking to process a large number of samples simultaneously or for a quicker turnaround time. This webinar will introduce a flexible and powerful setup for running your NGS sequence analyses through servers or Amazon Web Services (AWS), depending on user preference. We will demonstrate how CLC Genomics […]
Watch NowThere is a strong interest in the scientific community to use public (GEO, SRA, TCGA, LINCS, etc.) omics (RNA-seq, scRNA-seq, microarray, proteomics, etc.) data for a variety of discoveries. This webinar, aimed at data scientists, bioinformaticians and similar roles in biopharma and academia, explores a comprehensive way of accessing and analyzing high-quality, expertly curated omics […]
Watch NowYou’re invited to attend the 2024 Clinician’s Roundtable, a virtual event where medical directors and oncologists will discuss how to better interpret genomic test results to tailor treatment strategies for cancer patients. As the role of the Molecular Tumor Board (MTB) becomes increasingly important in the implementation of evidence-based precision cancer medicine programs, molecular pathology […]
Watch NowIngenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships knowledge has practically become required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many […]
Watch Now
